Clinical Interests
Dr, Muss is board-certified in Internal Medicine, Hematology, and Medical Oncology. His clinical interest is in cancer in older patients
and breast cancer with a focus on breast cancer in older patients.

Research Interests
Dr. Muss is a translational researcher who is involved in the design and of both clinical trials that contain collaborative trials involving both laboratory and health services research. His major interest is in cancer in older patients with a focus on the treatment of breast cancer in older women. Breast cancer is a disease of aging and the majority of women who die of breast cancer are 65 years and older. Older patients frequently receive poorer cancer treatment and Dr. Muss is interested in improving cancer care in such patients. He also has a major interest in adjuvant therapy and treatment of metastases. Dr. Muss and his colleagues at the Lineberger Cancer Center will be developing of program in geriatric
oncology. The aim of this program will be to educate physicians caring for cancer patients about the relevant issues affecting cancer care in elders, to develop clinical trials focused on older patients, and to implement the use of a short but accurate comprehensive geriatric assessment (CGA) tool that may
predict chemotherapy toxicity. In addition he will work with Dr. Sharpless in exploring the effects of cancer treatment in older patients on the expression of the P16INK4a gene. Dr. Sharpless and colleagues have found this gene increases dramatically with aging and may serve as a marker for the long term side effects of different therapies.

Recent Accomplishments and Honors
Past Chair, Subspecialty Board on Medical Oncology, American Board of Internal Medicine
Past member: Board of Directors, American Board of Internal Medicine
Co-Chair, Cancer in the Elderly Working Group, Cancer and Leukemia Group B
Recipient BJ Kennedy Award in Geriatric Oncology- American Society of Clinical Oncology 2008

Training
Lafayette College, Easton, PA , BA, 1964, Chemistry
State University of New York Downstate Medical Center, Brooklyn, New York, MD, 1968, Medicine
Internship and Residency: Peter Bent Brigham Hospital, Boston, MA
Fellowship in Hematology and Medical Oncology: Peter Bent Brigham Hospital and Dana-Farber Cancer Center, Boston , MA

Publications
1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB: Letrozole following tamoxifen as extended adjuvant therapy receptor positive
breast cancer. NCIC CTG MA-17. J Natl Cancer Inst 97:1262-71, 2005.
2. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, et al: Estrogenreceptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658-1667, 2006.
3. Cohen HJ, Muss HB: The Cancer and Leukemia Group B Cancer in the Elderly Committee: Addressing a major cancer need. Clin Cancer Res 12(11 Suppl)3606s-3611s, 2006.
4. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, et al: American Society of Clinical Oncology Breast Cancer
Surveillance 2006 Guideline Update American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and
Management Guidelines in the Adjuvant Setting. J Clin Onc 24(31):5091-5097, 2006.
5. Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, et al: Cyclin D-1, Interleukin-6, HER-2/neu, Transforming Growth Factor Receptor-II and Prediction of Relapse in Women with Early Stage, Hormone Receptor-Positive Breast Cancer Treated with Tamoxifen. The Breast Journal 13(4):337-345, 2007.
6. Muss HB, Berry Da, Cirrincione C, Budman D, Henderson IC, et al: Toxicity of Older and Young Patients Treated with Adjuvant
Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B (CALGB) Experience. J Clin Onc 25(24):3699-
3704, 2007.
7. Dittus K, Muss HB. Management of the frail elderly with breast cancer. Oncology (Williston Park) 21(14):1727-34; discussion
1737, 1740, 2007 Dec.
8. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio
RA, Bartelink H, Barton M, Giordano SH, Muss HB, Aapro M: International Society of Geriatric Oncology. Management of breast
cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol (12):1101-15.
Review 2007 Dec 8.
9. Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, et al: Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008 Feb 20;100(4):252-60. Epub 2008 Feb 12.
10. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ: Efficacy, toxicity, and quality of life in older women with early-stage breast
cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr
20;26(12):1956-64. Epub, 2008 Mar 10.
11. Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Harlow S,
Weaver D, Muss HB, Plaut K: Molecular signatures suggest a major role for stromal cells in development of invasive breast
cancer. Breast Cancer Res Treat. 2009 Mar;114(1):47-62, Epub, 2008 Mar 29.
12. Seidman AD, Berry D, Cirrincione C, Harris L, Muss HB: Randomized phase III trial of weekly compared with every-3-weeks
paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or
not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26(10):1642-9, 2008
Apr 1.
13. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB:
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol 10;26(14):2364-72, 2008 May.
14. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB: Tamoxifen and aromatase inhibitors differentially affect vascular
endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res. 2008 May 15;14(10):3070-6.
15. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss HB, et al: Racial differences in clinical outcomes from
metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.J Clin Oncol 26(16):2659-65,
2008 Jun 1.
16. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et al: Late extended adjuvant treatment with letrozole improves
outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55.
Epub 2008 Mar 10. Erratum in: J Clin Oncol 26(21):3659, 2008 Jul 20.
17. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M: Extended adjuvant endocrine therapy in breast cancer: current status and
future directions.Clin Breast Cancer; 8(5):411-7. Review, 2008 Oct.
18. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M: Extended adjuvant endocrine therapy in breast cancer: current status and
future directions.Clin Breast Cancer; 8(5):411-7. Review, 2008 Oct.
19. Grunberg SM, Dugan M, Muss HB, Wood M, Burdette-Radoux S, et al: Effectiveness of a single-day three-drug regimen of
dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately
emetogenic chemotherapy. Support Care Cancer, 2008 Nov 27.
20. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, et al: Adjuvant
Chemotherapy in Older Women with Early-Stage Breast Cancer. N Engl J Med 360: 2055-65, 2009.
21. Jones SE, Holmes FA, OShaughnessy JA, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J,
Hyman WJ, Khandelwal P, Negron AAG, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Ridel S, Muss HB, Savin MA: Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and
Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Onc 27:1177-1183, 2009.

E-mail: muss@email.unc.edu
Telephone: 966-4431
FAX: 843-3735
Address: 170 Manning Drive Chapel Hill, NC 27599

Click here to update this profile